News | August 13, 2024
Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Subscribe To Our Newsletter & Stay Updated
